GREY:IMVIQ - Post Discussion
Post by
Breakthorough1 on Aug 05, 2023 9:19am
Non-disclosed data
1- COVID (28-Dic-2020: "We are encouraged by the data generated thus far. Results are consistent with the mechanism of action of our DPX delivery platform demonstrated across prior clinical studies with DPX-based vaccines and cancer immunotherapies”)
2- MSI-H tumors (21-Dic-2021: "IMV Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts")
3- DPX-SurMage in Bladder: promised for first semester 2023
4- VITALIZE. All patients of Stage1 alreaby passed first scan ab the 10th of july.
Be the first to comment on this post